Showing results (531-540 of 1,188) with videos related to
Sort By:
Pageof 119
Blood Advances|November 10, 2020
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBetül Oran, Marcos de Lima, Guillermo Garcia-Manero, et al.Critical Reviews in Food Science and Nutrition|August 5, 2022
Truths and myths about superfoods in the era of the COVID-19 pandemicAbdo Hassoun, Rania Harastani, Sandeep Jagtap, et al.British Journal of Haematology|August 31, 2019
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyFevzi F Yalniz, Jesus G Berdeja, Michael B Maris, et al.Cancer|October 25, 2011
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicinFarhad Ravandi, Keyur Patel, Rajyalakshmi Luthra, et al.Leukemia Research|August 17, 2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopeniaGuillermo Garcia-Manero, Bart L Scott, Christopher R Cogle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.Blood|July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.British Journal of Haematology|February 25, 2012
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndromeTapan M Kadia, Gautam Borthakur, Guillermo Garcia-Manero, et al.American Journal of Hematology|January 19, 2026
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS StudyRami S Komrokji, Sheida Hayati, Manuel Ugidos, et al.Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.Pageof 119